Tags

Type your tag names separated by a space and hit enter

Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
Scand J Infect Dis. 2008; 40(6-7):523-6.SJ

Abstract

Miltefosine is the first effective oral drug against visceral leishmaniasis. However, there are few data about its role against the increasing problem of HIV-associated visceral leishmaniasis. It is necessary to establish a treatment and secondary prophylaxis approach with miltefosine in this population, particularly for those in whom standard treatment was unsuccessful. We report our experience with miltefosine in 5 HIV-infected patients. Miltefosine was used in relapse treatments (50 mg, b.i.d.) in 3 patients and as maintenance therapy (50 mg, 3 times/week) in all of them. Miltefosine was discontinued after full recovery of immune function in 4 patients. The median disease-free period has been 20 months since miltefosine discontinuation. One patient was lost to follow-up. Miltefosine dosage regimens for the treatment of relapses and for maintenance treatment in HIV-infected patients should be established in prospective studies.

Authors+Show Affiliations

Infectious Diseases Department, University Hospital of Coimbra, Coimbra, Portugal. lusonmar@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18584541

Citation

Marques, Nuno, et al. "Miltefosine for Visceral Leishmaniasis Relapse Treatment and Secondary Prophylaxis in HIV-infected Patients." Scandinavian Journal of Infectious Diseases, vol. 40, no. 6-7, 2008, pp. 523-6.
Marques N, Sá R, Coelho F, et al. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients. Scand J Infect Dis. 2008;40(6-7):523-6.
Marques, N., Sá, R., Coelho, F., Oliveira, J., Saraiva Da Cunha, J., & Meliço-Silvestre, A. (2008). Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients. Scandinavian Journal of Infectious Diseases, 40(6-7), 523-6. https://doi.org/10.1080/00365540701787800
Marques N, et al. Miltefosine for Visceral Leishmaniasis Relapse Treatment and Secondary Prophylaxis in HIV-infected Patients. Scand J Infect Dis. 2008;40(6-7):523-6. PubMed PMID: 18584541.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients. AU - Marques,Nuno, AU - Sá,Rosa, AU - Coelho,Filomena, AU - Oliveira,Joaquim, AU - Saraiva Da Cunha,J, AU - Meliço-Silvestre,A, PY - 2008/6/28/pubmed PY - 2008/9/10/medline PY - 2008/6/28/entrez SP - 523 EP - 6 JF - Scandinavian journal of infectious diseases JO - Scand J Infect Dis VL - 40 IS - 6-7 N2 - Miltefosine is the first effective oral drug against visceral leishmaniasis. However, there are few data about its role against the increasing problem of HIV-associated visceral leishmaniasis. It is necessary to establish a treatment and secondary prophylaxis approach with miltefosine in this population, particularly for those in whom standard treatment was unsuccessful. We report our experience with miltefosine in 5 HIV-infected patients. Miltefosine was used in relapse treatments (50 mg, b.i.d.) in 3 patients and as maintenance therapy (50 mg, 3 times/week) in all of them. Miltefosine was discontinued after full recovery of immune function in 4 patients. The median disease-free period has been 20 months since miltefosine discontinuation. One patient was lost to follow-up. Miltefosine dosage regimens for the treatment of relapses and for maintenance treatment in HIV-infected patients should be established in prospective studies. SN - 0036-5548 UR - https://www.unboundmedicine.com/medline/citation/18584541/Miltefosine_for_visceral_leishmaniasis_relapse_treatment_and_secondary_prophylaxis_in_HIV_infected_patients_ L2 - https://www.tandfonline.com/doi/full/10.1080/00365540701787800 DB - PRIME DP - Unbound Medicine ER -